Docusign raises FY2026 guidance after big Q2 win, shares soar

Shares of DocuSign (DOCU) surged after the company reported stronger-than-expected fiscal Q2 results, with adjusted EPS of $0.92 and revenue of $800.6 million, and subsequently raised its full-year revenue and billings guidance. This strong performance was attributed to the expanding adoption of its AI-enhanced Intelligent Agreement Management (IAM) platform and operational efficiencies. While analysts like Bank of America view DocuSign's "recovery story" as back on track and are bullish on IAM's long-term potential, they also suggest much of the near-term upside is already priced into the shares, highlighting a balanced outlook despite the positive momentum.

Analysis

DocuSign (DOCU) delivered a strong fiscal second-quarter performance, fueling an over 8% premarket share price increase. The company reported adjusted EPS of $0.92, exceeding consensus by 7 cents, on revenue of $800.6 million, a 9% year-over-year increase that also beat expectations. Critically, billings, a key indicator of future revenue, grew 13% year-over-year to $818 million, signaling robust demand. Management attributed this outperformance to the expanding adoption of its AI-enhanced Intelligent Agreement Management (IAM) platform. This strategic pivot is further supported by the company raising its full-year guidance for both revenue (to $3.19-$3.20 billion) and billings (to $3.34 billion, implying 7.4% YoY growth). While analysts from Wolfe Research and Bank of America view the results as confirmation that DocuSign's recovery is on track, Bank of America noted that go-to-market efforts for the nascent IAM platform are a work-in-progress and that the current valuation may have already priced in much of the near-term upside, despite raising their price target to $102.

Key Decisions for Investors

• Investors should view the strong Q2 beat and raised full-year guidance as validation of the company's strategic shift toward the higher-value Intelligent Agreement Management platform, which appears to be re-accelerating growth.
• Despite the positive results, consider the valuation and analyst commentary suggesting much of the near-term upside may be priced in; further significant share price appreciation might depend on sustained execution and IAM adoption.
• Monitor future billings growth and the contribution from new IAM products, as these will be the primary indicators of whether the company can successfully transition from its core eSignature business to a more strategic, higher-growth platform.